1. Home
  2. NEPH vs LGVN Comparison

NEPH vs LGVN Comparison

Compare NEPH & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$3.01

Market Cap

31.0M

Sector

Health Care

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$1.10

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEPH
LGVN
Founded
1997
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0M
34.0M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
NEPH
LGVN
Price
$3.01
$1.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$3.00
AVG Volume (30 Days)
24.3K
1.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
1000.00
50.76
EPS
0.11
N/A
Revenue
$18,789,000.00
$709,000.00
Revenue This Year
$11.24
N/A
Revenue Next Year
$11.58
$10.81
P/E Ratio
$26.82
N/A
Revenue Growth
32.67
N/A
52 Week Low
$1.78
$0.48
52 Week High
$6.42
$1.83

Technical Indicators

Market Signals
Indicator
NEPH
LGVN
Relative Strength Index (RSI) 44.52 58.37
Support Level $2.79 $0.52
Resistance Level $3.21 $1.23
Average True Range (ATR) 0.17 0.10
MACD 0.05 -0.01
Stochastic Oscillator 66.02 61.25

Price Performance

Historical Comparison
NEPH
LGVN

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: